Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma
NCT05867030 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL
Last updated 2023-10-17
Summary
A Phase Ib/III, Multicenter, double-blinded study of Parsaclisib, a PI3Kδ Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma
Conditions
Interventions
- DRUG
-
lenalidomide is administered orally
- DRUG
-
rituximab is administered intravenously
- DRUG
-
parsaclisib
parsaclisib is administered orally
Sponsors & Collaborators
-
Innovent Biologics (Suzhou) Co. Ltd.
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-07-28
- Primary Completion
- 2029-08-31
- Completion
- 2033-04-30
More Related Trials
-
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
NCT05583149 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
NCT01282476 ·Status: TERMINATED ·Phase: PHASE2
-
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
NCT07240194 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
NCT01693614 ·Status: COMPLETED ·Phase: PHASE2
-
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
NCT06651853 ·Status: RECRUITING ·Phase: PHASE2
-
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)
NCT04796922 ·Status: WITHDRAWN ·Phase: PHASE3
-
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
NCT00670358 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
NCT05564052 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL
NCT05178836 ·Status: UNKNOWN ·Phase: PHASE2
-
NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL
NCT06737250 ·Status: RECRUITING ·Phase: PHASE2
-
An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
NCT06693973 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
NCT06090539 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL
NCT06981988 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
NCT01938001 ·Status: COMPLETED ·Phase: PHASE3
-
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
NCT01476787 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase I/II Study of Diffuse Large B-cell Lymphoma
NCT04856137 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
NCT01466868 ·Status: TERMINATED ·Phase: PHASE2
-
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT02077166 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma
NCT03372837 ·Status: COMPLETED ·Phase: PHASE3
-
Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.
NCT06324994 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
NCT02049541 ·Status: COMPLETED ·Phase: PHASE1
-
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
NCT04635683 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)
NCT04129710 ·Status: RECRUITING ·Phase: PHASE2
-
A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide
NCT05771883 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
NCT01729104 ·Status: TERMINATED ·Phase: PHASE1